跳轉至內容
Merck
  • Influence of combined therapy with rosuvastatin and amitriptyline on the oxidation-reduction status in rats.

Influence of combined therapy with rosuvastatin and amitriptyline on the oxidation-reduction status in rats.

Acta poloniae pharmaceutica (2013-10-24)
Mariola Herbet, Monika Gawrońska-Grzywacz, Anna Graca, Ewa Jagiełło-Wójtowicz
摘要

The aim of the present study was to assess the impact of combined therapy with rosuvastatin (10 mg/kg) and amitriptyline (10 mg/kg) on oxidation-reduction status in the blood of rats. After 2-week application of drugs alone or their combination, the activity of glutathione peroxidase (GPX), glutathione reductase (GR) and total antioxidant status (TAS) were determined. It was noticed that combined therapy with rosuvastatin and amitriptyline significantly increased the activity of GPX in comparison to the group receiving only rosuvastatin and decreased the activity of GR in comparison to groups receiving only rosuvastatin or amitriptyline. However, the activity of these enzymes as a result of combined therapy was placed in the level of the control groups. Our studies indicated that the combined therapy with both drugs caused an increase of TAS compared to the groups of animals receiving only one of these drugs. The results indicate on the oxidation-reduction balance and increasing the antioxidant status in rats treated with rosuvastatin and amitriptyline.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
盐酸阿米替林 盐酸盐, ≥98% (TLC), powder
Sigma-Aldrich
谷胱甘肽还原酶 人, buffered aqueous solution, ≥10 units/mg protein, recombinant, expressed in E. coli
Supelco
阿米替林盐酸盐标准液 盐酸盐 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
USP
盐酸阿米替林 盐酸盐, United States Pharmacopeia (USP) Reference Standard
Supelco
盐酸阿米替林, Pharmaceutical Secondary Standard; Certified Reference Material
盐酸阿米替林 盐酸盐, European Pharmacopoeia (EP) Reference Standard